MMP11 Antibody - #AF0211

FIGURE 7 Validation of the mechanisms of GLXB treatment against AS in vivo. (A) The level of IL-6 in the serum of mice. (B) The level of IL-1β in the serum of mice. (C) The level of TNF-α in the serum of mice. (D) The level of ALOX5 in the serum of mice. (E) The expression of the p-p38 protein in the aorta of mice. (F) The level of PTGS2 in the serum of mice. (G) The expression of the p-AKT protein in the aorta of mice. (H) The level of VEGFA in the serum of mice. (I) The level of eNOS in the serum of mice. Data were expressed as mean ± SEM. * p < 0.05, ** p < 0.01. (J) The expressions of VCAM-1 and ICAM-1 proteins in the aorta of mice. Data were expressed as mean ± SEM. ** p < 0.01 vs. control group, ΔΔ p < 0.01 vs. GLXB group, # p < 0.05, ## p < 0.01 vs. model group. (K) Coimmunofluorescence staining of aortic tissue sections with antibodies to CD68 and α-SMA. Bar = 25 μm. (L) The level of TC in the serum of mice. (M) The level of TG in the serum of mice. (N) The level of LDL-C in the serum of mice. (O) The level of HDL-C in the serum of mice. Data were expressed as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01. GLXB: Gualou–Xiebai herb pair (6 g/kg); GL: Gualou (4 g/kg); XB: Xiebai (2 g/kg); ATO: atorvastatin (10 mg/kg).